Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/S ratio high or low?
The P/S ratio of 2.62 is 41% below its estimated 1-year average of 4.41, near the low end of its estimated 1-year range (2.51–5.49).
As of 2026-10-06T15:46:14.713Z.
Calculation as of: 2026-10-06T15:46:14.713Z.
Quote observation: 2026-10-06T15:43:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7e5dd7cae71be814523bfc9444594aa14e5919ebae0d9bfc7936539f469f7652
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
2.62
PS RATIO AVG TTM
N/A
PS RATIO AVG 3Y
N/A
PS RATIO AVG 5Y
N/A
PS RATIO AVG 10Y
N/A
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.17
median of 472 covered companies
CURRENT VS SECTOR MEDIAN
-37.25%
vs the sector median at left
Market Cap
$11.30M
PS Ratio
N/A
TTM Avg
3.04
3Y Avg
3.04
5Y Avg
6193.39
Market Cap
$11.44M
PS Ratio
N/A
TTM Avg
98.45
3Y Avg
233.47
5Y Avg
371.43
Market Cap
$10.93M
PS Ratio
109.28
TTM Avg
104.86
3Y Avg
73.15
5Y Avg
73.15
Market Cap
$10.52M
PS Ratio
N/A
TTM Avg
32.91
3Y Avg
62.07
5Y Avg
66.46
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cerenome, Inc. (CNSY) | $11.01M | 2.62 | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.63M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.30M | N/A | 3.04 | 3.04 | 6193.39 |
| Pluri Inc. (PLUR)vs › | $11.11M | 10.94 | 20.76 | 50.00 | 76.50 |
| BioVie Inc. (BIVI)vs › | $11.09M | N/A | N/A | N/A | N/A |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.44M | N/A | 98.45 | 233.47 | 371.43 |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.93M | 109.28 | 104.86 | 73.15 | 73.15 |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.52M | N/A | 32.91 | 62.07 | 66.46 |
| Biofrontera Inc. (BFRI)vs › | $11.82M | 0.26 | 0.28 | 0.18 | 0.48 |
| Lifeward Ltd. (LFWD)vs › | $10.57M | 0.48 | 0.51 | 1.36 | 4.08 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $1,397,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-30 |
| Q4 FY2025Period ended 2025-12-31 | $1,367,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-12 |
| Q1 FY2026Period ended 2026-03-31 | $1,028,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-15 |
| Q2 FY2026Period ended 2026-06-30 | $411,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-14 |
| TTM revenue | $4,203,000 |
Current P/S: $11,012,976 market capitalization ÷ $4,203,000 TTM revenue = 2.62x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T15:43:08.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
At 2.62, P/S is below its estimated 1-year median — higher than 3% of readings in its estimated 1-year history.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
estimated 1-year low
2.51
median
4.80
estimated 1-year high
5.49
P/S Ratio
2.62
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2026-10-05 | 2.51 |
| 2026-10-02 | 2.58 |
| 2026-10-01 | 2.87 |
| 2026-09-30 | 3.01 |
| 2026-09-29 | 3.00 |
| 2026-09-28 | 3.26 |
| 2026-09-25 | 3.21 |
| 2026-09-24 | 3.01 |
| 2026-09-23 | 3.14 |
| 2026-09-22 | 3.27 |
| 2026-09-21 | 3.06 |
| 2026-09-18 | 3.27 |
| 2026-09-17 | 3.27 |
| 2026-09-16 | 3.29 |
| 2026-09-15 | 3.42 |
| 2026-09-14 | 3.50 |
| 2026-09-11 | 3.75 |
| 2026-09-10 | 3.85 |
| 2026-09-09 | 4.01 |
| 2026-09-08 | 4.35 |
| 2026-09-04 | 4.45 |
| 2026-09-03 | 4.80 |
| 2026-09-02 | 4.74 |
| 2026-09-01 | 4.37 |
| 2026-08-31 | 4.54 |
| 2026-08-28 | 4.92 |
| 2026-08-27 | 5.00 |
| 2026-08-26 | 4.87 |
| 2026-08-25 | 4.98 |
| 2026-08-24 | 4.77 |
| 2026-08-21 | 4.95 |
| 2026-08-20 | 4.83 |
| 2026-08-19 | 5.14 |
| 2026-08-18 | 4.96 |
| 2026-08-17 | 5.16 |
| 2026-08-14 | 4.72 |
| 2026-08-13 | 4.75 |
| 2026-08-12 | 4.75 |
| 2026-08-11 | 4.91 |
| 2026-08-10 | 4.92 |
| 2026-08-07 | 4.91 |
| 2026-08-06 | 4.95 |
| 2026-08-05 | 5.01 |
| 2026-08-04 | 5.08 |
| 2026-08-03 | 4.51 |
| 2026-08-02 | 4.91 |
| 2026-07-31 | 4.96 |
| 2026-07-30 | 4.68 |
| 2026-07-29 | 4.66 |
| 2026-07-28 | 4.82 |
| 2026-07-27 | 4.78 |
| 2026-07-24 | 4.91 |
| 2026-07-23 | 4.85 |
| 2026-07-22 | 4.90 |
| 2026-07-21 | 5.03 |
| 2026-07-20 | 4.91 |
| 2026-07-17 | 4.80 |
| 2026-07-16 | 5.00 |
| 2026-07-15 | 5.23 |
| 2026-07-14 | 5.49 |
| 2026-07-13 | 5.35 |
| 2026-07-10 | 5.13 |
| 2026-07-09 | 5.13 |
| 2026-07-08 | 4.90 |
| 2026-07-07 | 5.03 |
| 2026-07-06 | 5.19 |
